Get started
Author

Varvara Polydoropoulou

Observed names: V Polydoropoulou, V. Polydoropoulou
OpenAlex ID: A5032010670
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2020 · S. Popat, A. Curioni-Fontecedro, et al. · Annals of Oncology · 281
PDF
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
2019 · U Dafni, O Michielin, et al. · Annals of Oncology · 271
PDF
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial
2016 · Sherene Loi, Urania Dafni, et al. · JAMA Oncology · 97
PDF
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
2017 · Igor Letovanec, Stephen Finn, et al. · Journal of Thoracic Oncology · 86
PDF
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2019 · S. Popat, A. Curioni-Fontecedro, et al. · Annals of Oncology · 56
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
2019 · Keith M. Kerr, Erik Thunnissen, et al. · Lung Cancer · 48
PDF
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project
2017 · K.M. Kerr, U. Dafni, et al. · Annals of Oncology · 45
PDF
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
2019 · Erik Thunnissen, Keith M. Kerr, et al. · Modern Pathology · 32
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
2018 · Martin Filipits, Urania Dafni, et al. · Clinical Cancer Research · 25
Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab
2018 · Scooter Willis, Varvara Polydoropoulou, et al. · JCO Precision Oncology · 7
Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.
2017 · Keith Kerr, Erik Thunnissen, et al. · Journal of Clinical Oncology · 1
Tables S1-S12, Figure S1-S3 from Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
2023 · Martin Filipits, Urania Dafni, et al.
Data from Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
2023 · Martin Filipits, Urania Dafni, et al.
Tables S1-S12, Figure S1-S3 from Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
2023 · Martin Filipits, Urania Dafni, et al.
Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort
2017 · K.M. Kerr, E. Thunnissen, et al. · Annals of Oncology
PDF
Abstract P5-18-01: TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial
2015 · Martin Filipits, Michael Gnant, et al. · Cancer Research
Abstract P3-06-02: Exploratory analysis of single gene predictive biomarkers in TransHERA DASL cohort reveals that C8A mRNA expression is prognostic of outcome and predictive of benefit of trastuzumab
2015 · Scooter Willis, Varvara Polydoropoulou, et al. · Cancer Research
Works count: 17
Citation count: 949
H-index: 9
I10-index: 9
Year
Topic
Type